Financhill
Sell
35

YBGJ Quote, Financials, Valuation and Earnings

Last price:
$0.0700
Seasonality move :
162.55%
Day range:
$0.0694 - $0.0740
52-week range:
$0.0310 - $1.2900
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.99x
P/B ratio:
--
Volume:
--
Avg. volume:
22.2K
1-year change:
-94.26%
Market cap:
$8.9M
Revenue:
$3.5K
EPS (TTM):
-$0.02

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Yubo International Biotech has -- downside to fair value with a price target of -- per share.

YBGJ vs. S&P 500

  • Over the past 5 trading days, Yubo International Biotech has underperformed the S&P 500 by -22.25% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Yubo International Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Yubo International Biotech revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Yubo International Biotech reported revenues of $3.5K.

Earnings Growth

  • Yubo International Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Yubo International Biotech reported earnings per share of --.
Enterprise value:
8.9M
EV / Invested capital:
--
Price / LTM sales:
12.99x
EV / EBIT:
--
EV / Revenue:
13.17x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-6.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-70.03%
Net Income Margin (TTM):
-282.62%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-11737.99%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $245.7K $455.7K -- $3.5K --
Gross Profit $102.1K $365.7K -- $2.7K --
Operating Income -$944.8K -$1.3M -$1.8M -$409.4K -$467.3K
EBITDA -$911.3K -$1.1M -$1.6M -$362.9K -$422.7K
Diluted EPS -$0.01 -$0.00 -$0.02 -- --
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $1.2M $910.1K $649.3K $734.9K $685.2K
Total Assets $3.9M $4.5M $2.1M $1.5M $1.2M
Current Liabilities $1.5M $3.3M $2.7M $3.5M $4.8M
Total Liabilities $3M $5.2M $3M $3.6M $4.8M
Total Equity $926.5K -$760.1K -$838.8K -$2.1M -$3.6M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$684.6K -$1M -$1.4M -$330.6K -$392.1K
Cash From Investing -$30.2K -$30K $142.3K -$30K -$6.2K
Cash From Financing $669.2K $1.1M $1.4M $308.2K $277.8K
Free Cash Flow -$714.8K -$1.1M -$1.4M -$360.6K -$398.2K
YBGJ
Sector
Market Cap
$8.9M
--
Price % of 52-Week High
5.74%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-94.26%
--
Beta (5-Year)
3.981
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.0806
200-day SMA
Buy
Level $0.0670
Bollinger Bands (100)
Buy
Level 0.058 - 0.078
Chaikin Money Flow
Sell
Level -12.1M
20-day SMA
Sell
Level $0.0809
Relative Strength Index (RSI14)
Sell
Level 47.6633
ADX Line
Sell
Level 15.2968
Williams %R
Neutral
Level -57.7348
50-day SMA
Sell
Level $0.0762
MACD (12, 26)
Buy
Level 0.0005
25-day Aroon Oscillator
Buy
Level 20
On Balance Volume
Neutral
Level 4.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-12.5213)
Sell
CA Score (Annual)
Level (-15.2979)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (1)
Sell
Ohlson Score
Level (26.6966)
Sell
Piotroski F Score (Annual)
Level (3)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.

Stock Forecast FAQ

In the current month, YBGJ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The YBGJ average analyst price target in the past 3 months is --.

  • Where Will Yubo International Biotech Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Yubo International Biotech share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Yubo International Biotech?

    Analysts are divided on their view about Yubo International Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Yubo International Biotech is a Sell and believe this share price will rise from its current level to --.

  • What Is Yubo International Biotech's Price Target?

    The price target for Yubo International Biotech over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is YBGJ A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Yubo International Biotech is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of YBGJ?

    You can purchase shares of Yubo International Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Yubo International Biotech shares.

  • What Is The Yubo International Biotech Share Price Today?

    Yubo International Biotech was last trading at $0.0700 per share. This represents the most recent stock quote for Yubo International Biotech. Yesterday, Yubo International Biotech closed at $0.0740 per share.

  • How To Buy Yubo International Biotech Stock Online?

    In order to purchase Yubo International Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 40.18% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is down 22.06% over the past day.

Buy
67
GBX alert for Jul 3

Greenbrier Companies [GBX] is up 21.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock